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A relatively new drug used in the treatment of osteo-
porosis, strontium ranelate has been associated with 
several side effects, including increased relative risk of 
venous thromboembolism (including pulmonary embo-
lism), transient increases in creatine kinase levels, mild 
gastrointestinal, nervous system and muscular disorders, 
and drug-induced hypersensitivity syndrome, also called 
DRESS syndrome (1). DRESS syndrome is a severe, 
acute drug reaction defined by the presence of fever, skin 
eruptions and systemic symptoms, including enlarged 
lymph nodes, abnormal liver function, renal impairment, 
and pulmonary and cardiac infiltrates, as well as haema-
tological abnormalities, primarily hypereosinophilia and 
lymphocytosis (2, 3). We report here a case of a patient 
with strontium ranelate-induced DRESS who developed 
persistent autoimmune hepatitis. 
CASE REPORT
A 69-year-old woman developed a skin rash with flu-like symp-
toms including fever (40°C) after taking strontium ranelate for 
four weeks. The strontium ranelate treatment was discontinued 
and methylprednisolone (16 mg/day) administered instead. After 
two weeks, and following a slight improvement in symptoms, 
steroid therapy was stopped. However, fever and generalised 
erythroderma developed again (Fig. 1). At this point, the patient 
was admitted to our clinic. Laboratory tests revealed the fol-
lowing: an erythrocyte sedimentation rate (ESR) of 11 mm/h 
(normal level < 20); a C-reactive protein (CRP) level of 55.6 mg/l 
(< 5); a white blood cell count of 16.47 × 109/l (3.9–11.1 × 109/l), 
of which 18 % were eosinophils (1.5–7.5%); thrombocytopenia 
(platelet count 137 × 109/l (169–358 × 109/l)); liver damage 
(glutamic-oxaloacetic transaminase (GOT) level 43 U/l (< 31), 
glutamic-pyruvic transaminase (GPT) level 60 U/l (< 31), alkaline 
phosphatase (ALP) level 326 U/l (< 240) and gamma-glutamyl 
transferase (GGT) level 128 U/l (< 32)); a normal serum biliru-
bin level; a serum carbamide level of 13.4 mmol/l (2.9–11.1); a 
serum creatinine level of 113 mmol/l (53–106); and proteinuria. 
The patient’s serum was negative for antinuclear antibodies 
(ANA). Analysis of a skin biopsy revealed extensive hydropic 
degeneration of basal keratinocytes, hyperkeratosis, granular 
spongiosis, keratinocyte necrosis and subepidermal eosinophilic 
infiltration. These findings were consistent with interface derma-
titis seen in erythema exsudativum multiforme (Fig. 2). Based 
on these findings, we diagnosed DRESS. Methylprednisolone 
(125 mg/day) was administered intravenously for 4 days. The 
dose was then gradually tapered and the drug later replaced with 
prednisolone. The maintenance dose was 20 mg daily (at lower 
doses, the skin symptoms reappeared). The results of laboratory 
tests returned to normal. Two months later, the patient developed 
deep vein thrombosis. Acenocoumarol therapy was commenced, 
and her maintenance steroid therapy stopped. Her skin symp-
toms reappeared within a week of the steroid treatment being 
discontinued. Methylprednisolone treatment was reintroduced 
at a dose of 32 mg/day, and (tapered to 4 mg every second day). 
Three months later, the patient again stopped the steroid therapy. 
Shortly afterwards, a mild skin rash again developed on her arms 
and legs. Fresh laboratory tests revealed an ESR of 18 mm/h 
and a serum CRP level of 26.3 mg/l, and indicated serious liver 
damage (GOT level 468 U/l, GPT level 867 U/l, ALP level 327 
U/l, GGT level 360 U/l, serum bilirubin level 22.1 mmol/l (< 19) 
and lactate dehydrogenase (LDH) level 613 U/l (< 530)). The 
patient’s serum was further found to be positive for ANA and 
smooth-muscle antigens (SMA). Serological tests (hepatitis B and 
C viruses, cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
herpes simplex virus (HSV)-1 and HSV-2) were negative. Col-
lectively, these results indicated the occurrence of autoimmune 
hepatitis. Low-dose prednisolone therapy was introduced again. 
The patient’s liver function test results improved 14 months 
after the initial appearance of DRESS. Presently she is taking 
Fig. 1. (A) Confluent maculopapular exanthema over the whole body. (B) 
Skin rash on the palm.
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prednisolone at a dose of 5 mg/day and her transaminase levels 
are normal. 
DISCUSSION
The most common triggering agents for DRESS are 
antiepileptic drugs, sulphonamides, antiretroviral 
drugs and allopurinol (4). Symptoms usually occur 
2–6 weeks after the initiation of drug therapy. Often, 
discontinuation of the medication is insufficient to 
combat them, with systemic steroid therapy also being 
necessary. Symptoms can be long-lasting and require 
long periods of steroid treatment. Some manifestations 
may be life-threatening, with a mortality rate of 10% 
(5, 6). Genetic predisposition, altered drug metabolism 
and concurrent viral or bacterial infections are thought 
to contribute to disease induction. Skin symptoms – the 
result of a delayed-type hypersensitivity reaction – are 
almost always present and, although they show some 
variation in appearance, take the form of maculopapular 
rashes. In histology analyses, characteristic interface 
dermatitis – mononuclear cell infiltrate in the papillary 
dermis and basal keratinocyte necrosis – is observed at 
the dermo-epidermal junction:  Moreover, the more ba-
sal keratinocyte cell death occurs, the more exfoliative 
the skin symptoms become, in severe cases resembling 
those associated with Stevens-Johnson syndrome and 
toxic epidermal necrolysis (7, 8).
To our knowledge this is the fifth reported case of 
DRESS syndrome associated with strontium ranelate. 
In one of the first two cases, the patient died of fulmi-
nant hepatitis linked to HHV6 virus reactivation, which 
was thought to have contributed to the development 
of DRESS syndrome (5). One case of bullous DRESS 
syndrome and one with renal failure have also been 
reported (9, 10). In our patient, autoimmune hepatitis 
was not related to reactivation of CMV, and serological 
tests for hepatitis B and C viruses, EBV, HSV-1 and 
HSV-2 were also negative (we did not test for HHV6 
reactivation). Autoimmune hepatitis developed after she 
had been treated for deep vein thrombosis for several 
months with acenocoumarol. The hepatitis that initially 
occurred as part of the DRESS syndrome improved 
following steroid treatment. At that time, the results of 
ANA testing were negative. We did not initially test for 
other antibodies that are considered to be important in 
autoimmune hepatitis. Because coumarins are known 
to induce hepatitis, we cannot exclude the possibility 
that the long-lasting autoimmune hepatitis was caused 
by coumarin treatment. It is also possible that the two 
drugs, strontium ranelate and coumarin, together con-
tributed to the development of liver disease. Because 
strontium ranelate increases the risk of thromboem-
bolism, similar combined therapies are likely to be 
administered to other patients in the future.
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Fig. 2. (A) Histology of a maculopapular skin lesion, showing interface 
dermatitis (haematoxylin and eosin (HE) ×200). (B) Magnified image showing 
extensive hydropic degeneration of basal keratinocytes and subepidermal 
eosinophilic infiltration (HE ×400).
